These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 31111862)

  • 1. Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels: A Prespecified Analysis of the Randomized BIO-RESORT Trial.
    Buiten RA; Ploumen EH; Zocca P; Doggen CJM; van der Heijden LC; Kok MM; Danse PW; Schotborgh CE; Scholte M; de Man FHAF; Linssen GCM; von Birgelen C
    JAMA Cardiol; 2019 Jul; 4(7):659-669. PubMed ID: 31111862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.
    von Birgelen C; Kok MM; van der Heijden LC; Danse PW; Schotborgh CE; Scholte M; Gin RMTJ; Somi S; van Houwelingen KG; Stoel MG; de Man FHAF; Louwerenburg JHW; Hartmann M; Zocca P; Linssen GCM; van der Palen J; Doggen CJM; Löwik MM
    Lancet; 2016 Nov; 388(10060):2607-2617. PubMed ID: 27806902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thin, Very Thin, or Ultrathin Strut Biodegradable or Durable Polymer-Coated Drug-Eluting Stents: 3-Year Outcomes of BIO-RESORT.
    Buiten RA; Ploumen EH; Zocca P; Doggen CJM; Danse PW; Schotborgh CE; Scholte M; van Houwelingen KG; Stoel MG; Hartmann M; Tjon Joe Gin RM; Somi S; Linssen GCM; Kok MM; von Birgelen C
    JACC Cardiovasc Interv; 2019 Sep; 12(17):1650-1660. PubMed ID: 31422087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial.
    Pilgrim T; Piccolo R; Heg D; Roffi M; Tüller D; Muller O; Moarof I; Siontis GCM; Cook S; Weilenmann D; Kaiser C; Cuculi F; Hunziker L; Eberli FR; Jüni P; Windecker S
    Lancet; 2018 Sep; 392(10149):737-746. PubMed ID: 30170848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronary bifurcations treated with thin-strut drug-eluting stents: a prespecified analysis of the randomized BIO-RESORT trial.
    Buiten RA; Warta S; Ploumen EH; Doggen CJM; van der Heijden LC; Hartmann M; Danse PW; Schotborgh CE; Scholte M; Linssen GCM; Zocca P; von Birgelen C
    Coron Artery Dis; 2021 Jan; 32(1):51-57. PubMed ID: 33278175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial.
    Zbinden R; Piccolo R; Heg D; Roffi M; Kurz DJ; Muller O; Vuilliomenet A; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Franzone A; Eberli F; Jüni P; Windecker S; Pilgrim T
    J Am Heart Assoc; 2016 Mar; 5(3):e003255. PubMed ID: 26979080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thin Composite-Wire-Strut Zotarolimus-Eluting Stents Versus Ultrathin-Strut Sirolimus-Eluting Stents in BIONYX at 2 Years.
    Buiten RA; Ploumen EH; Zocca P; Doggen CJM; Jessurun GAJ; Schotborgh CE; Roguin A; Danse PW; Benit E; Aminian A; van Houwelingen KG; Schramm AR; Stoel MG; Somi S; Hartmann M; Linssen GCM; von Birgelen C
    JACC Cardiovasc Interv; 2020 May; 13(9):1100-1109. PubMed ID: 32381186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial.
    Kandzari DE; Koolen JJ; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
    JACC Cardiovasc Interv; 2020 Jun; 13(11):1343-1353. PubMed ID: 32499026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.
    Iglesias JF; Muller O; Heg D; Roffi M; Kurz DJ; Moarof I; Weilenmann D; Kaiser C; Tapponnier M; Stortecky S; Losdat S; Eeckhout E; Valgimigli M; Odutayo A; Zwahlen M; Jüni P; Windecker S; Pilgrim T
    Lancet; 2019 Oct; 394(10205):1243-1253. PubMed ID: 31488372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents.
    Iglesias JF; Heg D; Roffi M; Tüller D; Lanz J; Rigamonti F; Muller O; Moarof I; Cook S; Weilenmann D; Kaiser C; Cuculi F; Valgimigli M; Jüni P; Windecker S; Pilgrim T
    J Am Heart Assoc; 2019 Nov; 8(22):e013607. PubMed ID: 31696762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of percutaneous coronary intervention using ultrathin-strut biodegradable polymer sirolimus-eluting versus thin-strut durable polymer zotarolimus-eluting stents in patients with comorbid peripheral arterial disease: a post-hoc analysis from two randomized trials.
    Pinxterhuis TH; Ploumen EH; Zocca P; Doggen CJM; Schotborgh CE; Anthonio RL; Roguin A; Danse PW; Benit E; Aminian A; van Houwelingen KG; Linssen GCM; Geelkerken RH; von Birgelen C
    Cardiovasc Diagn Ther; 2023 Aug; 13(4):673-685. PubMed ID: 37675090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final 3-Year Outcomes of MiStent Biodegradable Polymer Crystalline Sirolimus-Eluting Stent Versus Xience Permanent Polymer Everolimus-Eluting Stent: Insights From the DESSOLVE III All-Comers Randomized Trial.
    Takahashi K; Serruys PW; Kogame N; Buszman P; Lurz P; Jessurun GAJ; Koch KT; Troquay RPT; Hamer BJB; Oude Ophuis T; Milewski KP; Hofma SH; Wykrzykowska JJ; Onuma Y; de Winter RJ; Wijns W
    Circ Cardiovasc Interv; 2020 Jun; 13(6):e008737. PubMed ID: 32466676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial.
    Pilgrim T; Heg D; Roffi M; Tüller D; Muller O; Vuilliomenet A; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Fahrni T; Moschovitis A; Noble S; Eberli FR; Wenaweser P; Jüni P; Windecker S
    Lancet; 2014 Dec; 384(9960):2111-22. PubMed ID: 25189359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial.
    Iglesias JF; Heg D; Roffi M; Tüller D; Noble S; Muller O; Moarof I; Cook S; Weilenmann D; Kaiser C; Cuculi F; Häner J; Jüni P; Windecker S; Pilgrim T
    Circ Cardiovasc Interv; 2019 Aug; 12(8):e008024. PubMed ID: 31525083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients.
    Roguin A; Kandzari DE; Marcusohn E; Koolen JJ; Doros G; Massaro JM; Garcia-Garcia HM; Bennett J; Gharib EG; Cutlip DE; Waksman R
    Circ Cardiovasc Interv; 2018 Oct; 11(10):e007331. PubMed ID: 30354631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three contemporary thin-strut drug-eluting stents implanted in severely calcified coronary lesions of participants in a randomized all-comers trial.
    Buiten RA; Ploumen EH; Zocca P; Doggen CJM; van Houwelingen KG; Danse PW; Schotborgh CE; Stoel MG; Scholte M; Linssen GCM; de Man FHAF; von Birgelen C
    Catheter Cardiovasc Interv; 2020 Nov; 96(5):E508-E515. PubMed ID: 32237060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization.
    Yamaji K; Zanchin T; Zanchin C; Stortecky S; Koskinas KC; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Valgimigli M; Billinger M; Pilgrim T; Heg D; Windecker S; Räber L
    Circ Cardiovasc Interv; 2018 Sep; 11(9):e006741. PubMed ID: 30354590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents and Thin, Durable-Polymer Everolimus-Eluting Stents in Calcified or Small Vessel Lesions.
    Dan K; Garcia-Garcia HM; Kolm P; Windecker S; Saito S; Kandzari DE; Waksman R
    Circ Cardiovasc Interv; 2020 Sep; 13(9):e009189. PubMed ID: 32895004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
    Zocca P; Kok MM; Tandjung K; Danse PW; Jessurun GAJ; Hautvast RWM; van Houwelingen KG; Stoel MG; Schramm AR; Tjon Joe Gin RM; de Man FHAF; Hartmann M; Louwerenburg JHW; Linssen GCM; Löwik MM; Doggen CJM; von Birgelen C
    JACC Cardiovasc Interv; 2018 Mar; 11(5):462-469. PubMed ID: 29519378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial.
    Franzone A; Pilgrim T; Heg D; Roffi M; Tüller D; Vuilliomenet A; Muller O; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Räber L; Stortecky S; Wenaweser P; Jüni P; Windecker S
    Circ Cardiovasc Interv; 2015 Jun; 8(6):. PubMed ID: 26043895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.